Bunitrolol HCl | CAS# 23093-74-5 (HCl) | beta-adrenergic receptor antagonist

MedKoo Cat#: 414261 | Name: Bunitrolol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bunitrolol HCl is the salt form of Bunitrolol Free Base, a beta-adrenergic receptor antagonist with weak antiarrhythmic activity and minor ability to decrease the heart rate.

Chemical Structure

Bunitrolol HCl

CAS#23093-74-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 414261

Name: Bunitrolol HCl

CAS#: 23093-74-5 (HCl)

Chemical Formula: C14H21ClN2O2

Exact Mass: 0.0000

Molecular Weight: 284.78

Elemental Analysis: C, 59.05; H, 7.43; Cl, 12.45; N, 9.84; O, 11.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

23093-74-5 (HCl) 34915-68-9 (free base)

Synonym

Bunitrolol hydrochloride; Bunitrolol HCl; KO1366; KO-1366; KO 1366

IUPAC/Chemical Name

2-(3-tert-Butylamino-2-hydroxypropoxy)benzonitrile hydrochloride

InChi Key

RJPWESHPIMRNNM-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H20N2O2.ClH/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15;/h4-7,12,16-17H,9-10H2,1-3H3;1H

SMILES Code

N#CC1=CC=CC=C1OCC(O)CNC(C)(C)C.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 284.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Narimatsu S, Mizukami T, Huang Y, Masubuchi Y, Suzuki T. In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. J Pharm Pharmacol. 1996 Nov;48(11):1185-9. PubMed PMID: 8961170. 2: Ono S, Tsutsui M, Gonzalez FJ, Satoh T, Masubuchi Y, Horie T, Suzuki T, Narimatsu S. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics. 1995 Apr;5(2):97-102. PubMed PMID: 7663534. 3: Okabayashi T, Naito S, Arakawa K. Antihypertensive effect of intravenously and orally administered bunitrolol (Kö 1366). Arzneimittelforschung. 1979;29(9):1417-21. PubMed PMID: 42418. 4: Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull. 1994 Jun;17(6):803-7. PubMed PMID: 7951142. 5: Narimatsu S, Gotoh M, Masubuchi Y, Horie T, Ohmori S, Kitada M, Kageyama T, Asaoka K, Yamamoto I, Suzuki T. Stereoselectivity in bunitrolol 4-hydroxylation in liver microsomes from marmosets and Japanese monkeys. Biol Pharm Bull. 1996 Nov;19(11):1429-33. PubMed PMID: 8951158. 6: Haddad S, Poulin P, Funk C. Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine. J Pharm Sci. 2010 Oct;99(10):4406-26. doi: 10.1002/jps.22136. PubMed PMID: 20310018. 7: Tsuchihashi H, Aono J, Nagatomo T, Kawada T, Ohta H, Imai S. Effects of bunitrolol on adrenergic and serotonergic receptors. Jpn J Pharmacol. 1987 Nov;45(3):349-56. PubMed PMID: 2893855. 8: Chiba K, Hayase N, Ichihara K. Effects of bunitrolol on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Apr;82(4):384-8. PubMed PMID: 8096874. 9: Tsuchihashi H, Nagotomo T, Imai S. Selectivity of bunitrolol for beta 1- and beta 2-adrenergic receptors and 5HT1B-receptors: assessment by biphasic Scatchard plots and biphasic displacement curve analysis with 125I-iodocyanopindolol and 3H-CGP12177. Jpn J Pharmacol. 1989 Jun;50(2):93-100. PubMed PMID: 2570175. 10: Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90. PubMed PMID: 10206323. 11: Ishida R, Fujita S, Suzuki T. Bunitrolol metabolism and its inhibition by cimetidine. J Pharm Pharmacol. 1988 Jan;40(1):64-5. PubMed PMID: 2896780. 12: Beumer HM, Ritter W. Antagonism of fenoterol against beta-blocking drugs bunitrolol and practolol in asthmatics. Respiration. 1975;32(5):363-7. PubMed PMID: 241102. 13: Kawashima K, Miwa Y, Fujimoto K, Matsumoto J, Kimura M, Nagakura A. Hypotensive effect of bunitrolol at low plasma concentrations in conscious, unrestrained spontaneously hypertensive rats. Jpn J Pharmacol. 1985 Jul;38(3):259-65. PubMed PMID: 2865388. 14: Jonker JJ, de Klerk J, den Ottolander GJ. A double blind cross-over comparison of bunitrolol and placebo in the treatment of angina pectoris. Arzneimittelforschung. 1981;31(7):1140-2. PubMed PMID: 6115654. 15: Fujita S, Masuda M, Shimamoto Y, Hoshi H, Kariya S, Kazusaka A, Suzuki T. Effect of 3-methylcholanthrene on bunitrolol metabolism. Kinetics and immunological studies on 4-hydroxylation of bunitrolol catalyzed by two species of cytochromes P450 in rat liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):254-9. PubMed PMID: 8742239. 16: Satoh K, Nunoki K, Goto T, Taira N. The mechanism underlying the vasodilator action of bunitrolol: contribution of alpha 1-adrenoceptor blocking action. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):508-15. PubMed PMID: 2410682. 17: Masubuchi Y, Yamamoto K, Suzuki T, Horie T, Narimatsu S. Characterization of the oxidation reactions catalyzed by CYP2D enzyme in rat renal microsomes. Life Sci. 1996 May 24;58(26):2431-7. PubMed PMID: 8691988. 18: Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Effects of bunitrolol on myocardial contractility and left ventricular myosin isoenzyme pattern. Arzneimittelforschung. 1988 Sep;38(9):1280-2. PubMed PMID: 2906244. 19: Narimatsu S, Huang Y, Mizukami T, Masubuchi Y, Suzuki T. Development of a high-performance liquid chromatographic method for the analysis of enatiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes. Anal Biochem. 1994 Oct;222(1):256-61. PubMed PMID: 7856858. 20: Serizawa T, Iizuka M, Ohya T, Ohtani Y, Sugiura S, Koide T, Uchida Y, Morooka S, Kato A, Kimura Y, et al. Hemodynamic effect of bunitrolol on patients with ischemic heart disease. Comparison with propranolol. Jpn Heart J. 1987 May;28(3):367-75. PubMed PMID: 2887672.